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This is discussed fully in the next issue in an article by
Cohen et al. The problem is that rifampicin is a powerful
enzyme inducer that leads to enhanced metabolism of
protease inhibitors (except rironavir) and, ro a lesser exrent,
non-nucleoside reverse rranscriprase inhibirors. Rifampicin
levels are not significanrly affecred by antiretroviral
herapy. Antiretroviral drugs that can be used
concomiranrly wirh rifampicin are listed in Table 11.
Suirable antiretroviral regimens for patients on rifampicin
therefore include:
• Triple nucleoside RTI (effective provided the viral load is
< 50000 copies/ml or < 100 000 copies/mI if abacavir
is used)
• ua nucleoside RTI plus efavirenz
• Dua nucleoside RTI plus rironavir (or rironavir plus
saquinavir).
Rifabutin is a less porent enzyme inducer than rifampicin,
and certain protease inhibitors affect its levels. Rifabutin
can be used as an alternative to rifampicin in the treatment
of tuberculosis and is recommended as an alternative to
rifampicin in industria ised counrries, bur ir is expensive
and not available at southern African srare clinics where
tuberculosis 's treated. For [his reason it is not considered
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SHARED TOXlCITY
USING ANTIRETROVIRAL THERAPY IN
PATIENTS WITH TUBERCULOSIS
Tuberculosis is the commonest cause of morbidity and
mortality in HIV-infected patients in sub-Saharan Africa.
With increasing access to antiretroviral therapy in the
region, it is inevitable that large numbers of patients will
either develop tuberculosis while on antiretroviral therapy
or be considered for anriretroviral therapy when
tuberculosis develops. There are complex drug inreracrions
and shared roxicity of anrire-roviral and tuberculosis
therapy rhat need to be considered. Furrhermore,
anrirerroviral therapy can lead to paradoxical dererioration
of tuberculosis. This arricle reviews rhese complex
interactions and provides recommendations for using
antiretroviral and tuberculosis therapy in the southern
African context.
Snared or overlapping roxicity is common and leads ro
difficult managemenr decisions if the roxicity warranrs
stopping therapy. The commonest shared toxicities are
peripheral neuropathy, nausea, rash and hepatitis.
Peripheral neuropathy due to isoniazid can be prevenred
wirh pyridoxine, and it is prudent ro give this to all HIV-
in'ected parienrs even if rhey are nor on an iretroviral
rherapy, as periphera neuropatny is commonly due ro HIV.
Or gs that are "kely ro be res onsible are lis eo ·n
Tabe I.
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TABLE 11. DRUG INTERACTIONS BETWEEN RIFAMPION AND ANTIRETROVlRAl THERAPY
STARTING ANnRETROVIRAl THERAPY WITH NEWLY
DIAGNOSED TUBERCULOSIS
therapy should be at least 9 mon·hs. S!feptomycin should
be continued for as long as wleraled and regular
audiograms should be done to check for ototoxicity, which
is often irreversible.
RECOMMWDED READING
In areas where tuberculosis is endemic, like southern Africa,
HIV-infected patients develop tuberculosis with a wide
range of immune suppression. Tuberculosis per se should
therefore not be considered a criterion for staning
antiretroviral therapy. Because of the problems of
paradoxical reactions, drug interactions and shared toxicity
discussed above, antiretroviral therapy should not be
commenced at the same time as antituberculosis therapy.
Deciding when to start amiretroviral therapy depends on
lhe CD4+ Iymphocyte count and other serious HIV-related
co-morbidity:
• CD4 > 200 cells/~1. Defer antiretroviral therapy until
aher antituberculosis therapy. As CD4 counts tend to
increase when wberculosis is !fealed, lhese should be
repealed aher amiwberculosis therapy w see if the
patient needs antiretroviral therapy.
• CD4 50 - 200 cells/~1 Defer antiretroviral therapy
until aher the intensive phase (2 months) of
antituberculosis therapy. At this slage the number of
antituberculosis drugs is reduced, witn less chance of
shared toxicity, and {he risk of paradoxical reactions is
lower.
• Serious HIV-related co-morbidity or CD4 < 50
cells/~1 Slar antiretroviral therapy once il is clear that
he patien is wlerating ami uberculosis therapy. Tnis
will generally be aher about 2 weeks.
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No interactions
Mild reduction in efavirenz levels - some experts increase the dose to 800 mg
Moderate reduction in nevirapine levels - limited experience
No significant interaction
No significant interaction





Ritonavir + saquinavir (both 400 mg b.d.)
All other protease inhibirors
PARADOXICAL WORSENING OF TUBERCULOSIS
The mechanism of the paradoxical reactions is believed to
be due to the host immune response - either because of
increased antigen release following antituberculosis
therapy or because of immune reconstitution from
antirenoviral lherapy. Tne latter is known as immune
restoration syndrome and typically occurs in patients who
initiate highly active antiretroviral therapy with low CD4+
Iymphocyte counts. The other pathogens that are
"requently associaled with immune restoralion syndromes
are cytomegalovirus and Mycobacterium avium complex.
TREATING TUBERCULOSIS DEVElOPING ON
ANnRETROVIRAl nHERAPY
Paradoxical deterioralion of tuberculosis despite effective
antiwberculosis therapy was well documented in the pre-
HIV era. Typical cases observed were enlargement of lymph
nodes or tuberculomas. Paradoxical reactions occur far
more commcn!y in HiV-infected patients and include
wcrsening or new pulmonary infil'rates. In most case
series the paradoxical reactions are temporally related to
the initiation of antiretroviral therapy (especially when this
is commenced wilhin the first 2 momhs of antituberculosis
therapy), occurring in about a third of palients.
Rifampicin-based shon-course therapy is well studied and
highly effenive in !feating HIV-associa ed tuberculosis.
There are limiled data on treating tuberculosis in HIV-
infected patients without using rifamycins. Regimens
containing strepwmycin appear to be best, but the
duralion of lherapy is uncertain and the wxicily is
considerable. When patients develop tuberculosis while on
amiretroviral therapy it is therefore extremely important to
try to switch the patient to an antiretroviral regimen that
can be used with rifampicin. In most inslances a switch is
possible. If tnis is not possible, lhe sensitivily of the
organism should be checked. Tnerapy snould be
commenced (while awaiting the sensitivily resulls) wilh
isoniazid, pyrazinamide, ethambuwl and streptomycin -
lhe laITer can be given 3 times a week. The duralion of
